Sientra Inc (NASDAQ:SIEN) has been given an average recommendation of “Buy” by the twelve analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $15.75.
SIEN has been the subject of several research analyst reports. Canaccord Genuity upped their price target on shares of Sientra from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Wells Fargo & Co upgraded shares of Sientra from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $8.00 to $10.00 in a report on Wednesday, June 5th. Zacks Investment Research downgraded shares of Sientra from a “buy” rating to a “hold” rating in a report on Thursday. BidaskClub upgraded shares of Sientra from a “strong sell” rating to a “sell” rating in a report on Thursday, April 25th. Finally, Craig Hallum lowered their price target on shares of Sientra from $20.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, July 25th.
Shares of NASDAQ:SIEN traded down $0.03 during trading on Wednesday, hitting $6.89. 25,037 shares of the company were exchanged, compared to its average volume of 1,389,470. The business’s 50 day moving average is $5.91 and its 200-day moving average is $7.79. The company has a market capitalization of $315.95 million, a P/E ratio of -2.12 and a beta of 0.29. The company has a quick ratio of 1.16, a current ratio of 2.33 and a debt-to-equity ratio of 0.18. Sientra has a 1-year low of $4.78 and a 1-year high of $26.65.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.50). The company had revenue of $20.53 million for the quarter, compared to analyst estimates of $19.04 million. Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.73) earnings per share. As a group, sell-side analysts anticipate that Sientra will post -2.4 earnings per share for the current year.
In other Sientra news, CFO Paul Sean Little purchased 17,391 shares of the firm’s stock in a transaction on Friday, June 7th. The stock was purchased at an average cost of $5.75 per share, for a total transaction of $99,998.25. Following the acquisition, the chief financial officer now owns 94,891 shares in the company, valued at approximately $545,623.25. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Keith J. Sullivan purchased 20,869 shares of the firm’s stock in a transaction on Friday, June 7th. The shares were acquired at an average price of $5.75 per share, with a total value of $119,996.75. Following the completion of the acquisition, the director now owns 203,141 shares in the company, valued at approximately $1,168,060.75. The disclosure for this purchase can be found here. Corporate insiders own 13.30% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Formula Growth Ltd. grew its holdings in Sientra by 9.1% during the 1st quarter. Formula Growth Ltd. now owns 120,000 shares of the medical instruments supplier’s stock worth $1,030,000 after acquiring an additional 10,000 shares during the period. Tarbox Family Office Inc. grew its holdings in Sientra by 273.9% during the 1st quarter. Tarbox Family Office Inc. now owns 36,400 shares of the medical instruments supplier’s stock worth $312,000 after acquiring an additional 26,666 shares during the period. Geode Capital Management LLC grew its holdings in Sientra by 10.0% during the 4th quarter. Geode Capital Management LLC now owns 254,747 shares of the medical instruments supplier’s stock worth $3,237,000 after acquiring an additional 23,117 shares during the period. Bailard Inc. acquired a new stake in Sientra during the 1st quarter worth about $166,000. Finally, Stephens Inc. AR boosted its position in shares of Sientra by 155.1% during the 1st quarter. Stephens Inc. AR now owns 140,700 shares of the medical instruments supplier’s stock worth $1,207,000 after purchasing an additional 85,550 shares in the last quarter. Hedge funds and other institutional investors own 96.69% of the company’s stock.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Further Reading: What are the benefits of momentum investing?
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.